Abstract
β-(1,3)-Glucans are widely distributed within microorganisms or seaweeds in which they act as membrane components or for energy storage, respectively. Since these glucans are not biosynthesized by mammals, they are likely to activate the immune system of their host. Since the discovery of their positive involvement as immunomodulator agents, numerous studies were published all around the glycosciences. These works deal with purification procedures, analytical chemistry, synthetic processes, chemical modification of the natural polysaccharides, determination of their physicochemical properties, and assessment of their biological and medicinal effects through in vitro and in vivo studies. This article aims at presenting some recent results linked to β-(1,3)-glucans through two closely connected points of view, i.e. biology and chemistry. Biological aspects will be focused more particularly on discovery of some receptors present on immunocompetent cells and scope and limitations of chemical synthesis and/or modifications will be described. Moreover, this paper will also introduce some new chemo-enzymatic synthetic methods using wild-type or mutant glycosidases and will be extended to novel opportunities of applications of β-(1,3)-glucans in nanotechnology resulting from a better understanding of their self-assembling propensity in aqueous media.
Keywords: β-(1,3)-Glucans, receptors of β-(1,3)-glucans, immunostimulation, chemical modification, synthesis
Mini-Reviews in Medicinal Chemistry
Title: Recent Progress in the Field of β-(1,3)-Glucans and New Applications
Volume: 6 Issue: 12
Author(s): Karine Descroix, Vincent Ferrieres, Frank Jamois, Jean-Claude Yvin and Daniel Plusquellec
Affiliation:
Keywords: β-(1,3)-Glucans, receptors of β-(1,3)-glucans, immunostimulation, chemical modification, synthesis
Abstract: β-(1,3)-Glucans are widely distributed within microorganisms or seaweeds in which they act as membrane components or for energy storage, respectively. Since these glucans are not biosynthesized by mammals, they are likely to activate the immune system of their host. Since the discovery of their positive involvement as immunomodulator agents, numerous studies were published all around the glycosciences. These works deal with purification procedures, analytical chemistry, synthetic processes, chemical modification of the natural polysaccharides, determination of their physicochemical properties, and assessment of their biological and medicinal effects through in vitro and in vivo studies. This article aims at presenting some recent results linked to β-(1,3)-glucans through two closely connected points of view, i.e. biology and chemistry. Biological aspects will be focused more particularly on discovery of some receptors present on immunocompetent cells and scope and limitations of chemical synthesis and/or modifications will be described. Moreover, this paper will also introduce some new chemo-enzymatic synthetic methods using wild-type or mutant glycosidases and will be extended to novel opportunities of applications of β-(1,3)-glucans in nanotechnology resulting from a better understanding of their self-assembling propensity in aqueous media.
Export Options
About this article
Cite this article as:
Descroix Karine, Ferrieres Vincent, Jamois Frank, Yvin Jean-Claude and Plusquellec Daniel, Recent Progress in the Field of β-(1,3)-Glucans and New Applications, Mini-Reviews in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/138955706778993058
DOI https://dx.doi.org/10.2174/138955706778993058 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Targeting Ras Activity Prevented Amyloid Beta-Induced Aberrant Neuronal Cell Cycle Re-Entry and Death
Current Alzheimer Research NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors
Mini-Reviews in Medicinal Chemistry Preclinical and Clinical Studies on the Use of Stem Cells for Bone Repair: A Systematic Review
Current Stem Cell Research & Therapy Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents DNA and RNA Aptamers as Modulators of Protein Function
Medicinal Chemistry Liposomal Drug Delivery System for Cancer Therapy: Advancement and Patents
Recent Patents on Drug Delivery & Formulation Telomerase as Drug and Drug Target for the Treatment of Thyroid Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Chartreusin, Elsamicin A and Related Anti-Cancer Antibiotics
Current Medicinal Chemistry - Anti-Cancer Agents Preclinical Evaluation of New Taxoids
Current Pharmaceutical Design